Literature DB >> 12422135

New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.

John W Funder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12422135     DOI： 10.1067/mhj.2002.129971

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  9 in total

1.  Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass.

Authors:  Robert M Carey; Alexander G Logan
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 2.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

Review 3.  Aldosterone: good guy or bad guy in cerebrovascular disease?

Authors:  Christiné S Rigsby; William E Cannady; Anne M Dorrance
Journal:  Trends Endocrinol Metab       Date:  2005-10-06       Impact factor: 12.015

4.  Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.

Authors:  Pingping Yang; Wen Shen; Xi Chen; Dan Zhu; Xiuxiu Xu; Tao Wu; Gaosi Xu; Qinghua Wu
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

Review 5.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 6.  Aldosterone and aldosterone antagonism in systemic hypertension.

Authors:  William H Frishman; Charles T Stier
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 7.  Aldosterone--a hormone of cardiovascular adaptation and maladaptation.

Authors:  Theodore L Goodfriend
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

8.  Neuroendocrine humoral and vascular components in the pressor pathway for brain angiotensin II: a new axis in long term blood pressure control.

Authors:  John M Hamlyn; Cristina I Linde; Junjie Gao; Bing S Huang; Vera A Golovina; Mordecai P Blaustein; Frans H H Leenen
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

9.  ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?

Authors:  George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-06       Impact factor: 3.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.